---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-006932"
form_type: "8-K"
ticker: "TECH"
cik: "0000842023"
company_name: "BIO-TECHNE Corp"
filed_at: "2022-05-04T23:59:59+00:00"
generated_at: "2026-06-26T01:03:01.804689+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bio-Techne Q3 FY2022 revenue $290.4M (+17% organic), record adj. EPS $2.14

## Summary
- Q3 organic revenue +17% to $290.4M (reported +19%); YTD organic +18% to $817.4M.
- Record adjusted EPS $2.14 (GAAP EPS $1.48) vs $1.80 prior year.
- Protein Sciences organic +16%; Diagnostics & Genomics organic +19%.
- Declared quarterly dividend $0.32/share, payable May 27 to holders of record May 16.
- Announced exclusive agreement with Thermo Fisher to commercialize ExoTRU kidney transplant test.

## SEC filing metadata
- accession: 0001558370-22-006932
- form_type: 8-K
- ticker: TECH
- cik: 0000842023
- company_name: BIO-TECHNE Corp
- filed_at: 2022-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/842023/000155837022006932/0001558370-22-006932-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/842023/000155837022006932/tmb-20220504x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-006932
- JSON: https://secwatch.observer/filing/0001558370-22-006932.json
- Plain text: https://secwatch.observer/filing/0001558370-22-006932.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.